4. Conclusions
Porous CH-BG scaffolds were developed for use in bone tis-sue engineering applications. The antibiotic gentamicin sulfate wasentrapped into the scaffolds via the freeze-drying method to con-fer them the drug release capability. The increase of specific surfacearea, average pore diameter and pore volume are observed whenthe content of chitosan is more important than that of bioactiveglass 46S6. The in vitro assays of scaffolds in PBS show than therelease of gentamicin sulfate increases with these three parame-ters. This drug was released in a controlled manner. The release rate,the relaxation time of scaffolds and the limit concentration werealso dependent on the gentamicin sulfate concentration introducedin the beginning. Present CH-BG scaffolds, exhibiting a bioactivecharacter in SBF and controlled release ability of an antibiotic, areproposed for bone tissue engineering. These biomaterials could beadapted at a clinical application and according to the advance ofinfection to treat. Scaffolds represent a new type of biomaterials inthe field of therapeutic materials for the tissue engineering.AcknowledgementsAuthors would like to acknowledge J. Le Lannic and F. Perron(CMEBA, University of Rennes 1) for all micrographs. R. Ollitraultand E. Jullion for their help for the UV spectrophotometer analyses.CNRST, Maroc for the support by FINCOME program.